Edwards Lifesciences today announced it received CE Mark for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the heart's mitral position. The MITRIS RESILIA valve is made with bovine pericardial tissue technology that reduces calcium build up on the valve. This technology preserves and protects the tissue, allowing the valve to potentially last longer than conventional bioprosthetic valves.
The MITRIS RESILIA valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve. The low-profile valve is based on the Edwards PERIMOUNT valve design with a nitinol wireform, which allows it to fold inward during implantation. The MITRIS RESILIA valve is visible under fluoroscopy, which facilitates potential future transcatheter interventions for patients.
Recent data on the RESILIA tissue from the COMMENCE aortic trial reported encouraging results with low rates of structural valve deterioration (99.3% freedom from structural valve deterioration), clinically stable gradients and freedom from reoperation (97.2%) through seven years. Additionally, the COMMENCE mitral trial demonstrated clinically stable hemodynamics and freedom from structural valve deterioration (98,7%) at 5 years.
The RESILIA anti-calcification technology also allows devices to be stored under dry packaging conditions, facilitating ease of use.
Edwards is dedicated to partnering with clinicians to develop patient-centric innovations for complex surgical structural heart procedures that improve long-term care and outcomes for patients.
The MITRIS RESILIA valve received FDA approval in 2022 in the United States. The introduction of the MITRIS RESILIA valve into the portfolio demonstrates Edwards’ continuous investment in innovation for the benefits and the quality of life of patients.
